{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:19:27Z","timestamp":1784758767304,"version":"3.55.0"},"reference-count":112,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Health &amp; Medical Research Council, National Heart Foundation, NSW Ministry of Health (Senior Researcher Grant) and a CRC-Project (LMK)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Jun\/JUN is a basic leucine zipper (bZIP) protein and a prototypic member of the activator protein-1 (AP-1) family of transcription factors that can act as homo- or heterodimers, interact with DNA elements and co-factors, and regulate gene transcription. Jun is expressed by both immune and inflammatory cells. Jun is traditionally seen as an oncoprotein that regulates processes involved in transformation and oncogenesis in human tumours. This article examines the traditional view that Jun plays a permissive role in cancer development and progression, whilst exploring emerging evidence supporting Jun\u2019s potential to prevent immune cell exhaustion and promote anti-tumour efficacy.<\/jats:p>","DOI":"10.3390\/ijms26020555","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T06:25:54Z","timestamp":1736490354000},"page":"555","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Jun, an Oncological Foe or Friend?"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3092-9104","authenticated-orcid":false,"given":"Zuhayr","family":"Jafri","sequence":"first","affiliation":[{"name":"Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor H.","family":"O\u2019Meara","sequence":"additional","affiliation":[{"name":"Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia"},{"name":"Division of Head & Neck Oncology and Microvascular Reconstruction, Department of Otolaryngology, Head & Neck Surgery, University of Virginia Health Services, Charlottesville, VA 22903, USA"},{"name":"Department of Otolaryngology, Head & Neck Surgery, Australian National University, Acton, ACT 0200, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-0323","authenticated-orcid":false,"given":"Levon M.","family":"Khachigian","sequence":"additional","affiliation":[{"name":"Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.2834","article-title":"The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells","volume":"15","author":"Kurachi","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0898-6568(01)00275-3","article-title":"Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor","volume":"14","author":"Dunn","year":"2002","journal-title":"Cell. Signal."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-020-01686-9","article-title":"Selective antagonism of cJun for cancer therapy","volume":"39","author":"Brennan","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1093\/emboj\/cdg388","article-title":"A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun","volume":"22","author":"Morton","year":"2003","journal-title":"Embo J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2007.03.009","article-title":"Rewired ERK-JNK signaling pathways in melanoma","volume":"11","author":"Huang","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107731","DOI":"10.1016\/j.celrep.2020.107731","article-title":"Failed Apoptosis Enhances Melanoma Cancer Cell Aggressiveness","volume":"31","author":"Berthenet","year":"2020","journal-title":"Cell Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.18632\/oncotarget.6797","article-title":"HDAC inhibitors suppress c-Jun\/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells","volume":"7","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.18632\/aging.102372","article-title":"T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma","volume":"11","author":"Zhong","year":"2019","journal-title":"Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1541-7786.MCR-22-0695","article-title":"Targeting c-Jun Is a Potential Therapy for Luminal Breast Cancer Bone Metastasis","volume":"21","author":"Han","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(12)62166-7","article-title":"Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: A phase 1 first-in-human trial (DISCOVER)","volume":"381","author":"Cho","year":"2013","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2867-10-9","article-title":"Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours","volume":"10","author":"Tan","year":"2010","journal-title":"Cancer Cell Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4161\/cbt.7.8.6301","article-title":"Involvement of c-jun in human liposarcoma growth: Supporting data from clinical immunohistochemistry and DNAzyme efficacy","volume":"7","author":"Dass","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/jnci\/djh120","article-title":"Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents","volume":"96","author":"Zhang","year":"2004","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scitranslmed.3003960","article-title":"DNAzyme Targeting c-jun Suppresses Skin Cancer Growth","volume":"4","author":"Cai","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1038\/s41388-018-0306-0","article-title":"Melanoma protective antitumor immunity activated by catalytic DNA","volume":"37","author":"Cai","year":"2018","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: Interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Vara","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41419-019-1821-9","article-title":"C-Jun drives melanoma progression in PTEN wild type melanoma cells","volume":"10","author":"Gebhard","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of Advanced Melanoma in 2020 and Beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scisignal.aab1111","article-title":"The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma","volume":"8","author":"Ramsdale","year":"2015","journal-title":"Sci. Signal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15250","DOI":"10.18632\/oncotarget.3888","article-title":"The c-Jun\/RHOB\/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors","volume":"6","author":"Delmas","year":"2015","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109420","DOI":"10.1016\/j.intimp.2022.109420","article-title":"Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma","volume":"113","author":"Zhang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","first-page":"1207","article-title":"c-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy","volume":"18","author":"Zhang","year":"2007","journal-title":"Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Pu, X., Shi, M., Chen, L., Song, Y., Qian, L., Yuan, G., Zhang, H., Yu, M., and Hu, M. (2007). Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-145"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1947601913485413","article-title":"c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade","volume":"4","author":"Ebelt","year":"2013","journal-title":"Genes Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10735-024-10195-4","article-title":"An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies","volume":"55","author":"Anju","year":"2024","journal-title":"J. Mol. Histol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/path.4379","article-title":"c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas","volume":"234","author":"Sioletic","year":"2014","journal-title":"J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"25251","DOI":"10.18632\/oncotarget.15694","article-title":"RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.21037\/atm-21-2563","article-title":"Silencing c-Jun inhibits autophagy and abrogates radioresistance in nasopharyngeal carcinoma by activating the PI3K\/AKT\/mTOR pathway","volume":"9","author":"Sun","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: Past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fardini, Y., Dehennaut, V., Lefebvre, T., and Issad, T. (2013). O-GlcNAcylation: A New Cancer Hallmark?. Front. Endocrinol., 4.","DOI":"10.3389\/fendo.2013.00099"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109384","DOI":"10.1016\/j.cellsig.2019.109384","article-title":"O-GlcNAcylated c-Jun antagonizes ferroptosis via inhibiting GSH synthesis in liver cancer","volume":"63","author":"Chen","year":"2019","journal-title":"Cell Signal"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e37344","DOI":"10.1016\/j.heliyon.2024.e37344","article-title":"A novel biomarker GATM suppresses proliferation and malignancy of cholangiocarcinoma cells by modulating the JNK\/c-Jun signalling pathways","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11321","DOI":"10.1038\/ncomms11321","article-title":"The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy","volume":"7","author":"Lukey","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1601-0825.2008.01471.x","article-title":"The tumour microenvironment: A novel target for cancer therapy","volume":"15","author":"Hanna","year":"2009","journal-title":"Oral Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc2067","article-title":"The tumour microenvironment as a target for chemoprevention","volume":"7","author":"Albini","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1152\/physrev.00008.2020","article-title":"Moving immune therapy forward targeting tme","volume":"101","author":"Goliwas","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114137","DOI":"10.1016\/j.addr.2022.114137","article-title":"Strategies targeting tumor immune and stromal microenvironment and their clinical relevance","volume":"183","author":"Hu","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sanford-Crane, H., Abrego, J., and Sherman, M.H. (2019). Fibroblasts as Modulators of Local and Systemic Cancer Metabolism. Cancers, 11.","DOI":"10.3390\/cancers11050619"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nihashi, Y., Song, X., Yamamoto, M., Setoyama, D., and Kida, Y.S. (2023). Decoding Metabolic Symbiosis between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts Using Cultured Tumor Microenvironment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311015"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.7150\/thno.75853","article-title":"Enhancer reprogramming promotes the activation of cancer-associated fibroblasts and breast cancer metastasis","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: From Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1333213","DOI":"10.1080\/2162402X.2017.1333213","article-title":"Colony-stimulating factor-1-induced AIF1 expression in tumor-associated macrophages enhances the progression of hepatocellular carcinoma","volume":"6","author":"Cai","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51840","DOI":"10.18632\/oncotarget.10123","article-title":"Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer","volume":"7","author":"Song","year":"2016","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lee, H.J., and Oh, J.Y. (2024). Mesenchymal Stem\/Stromal Cells Induce Myeloid-Derived Suppressor Cells in the Bone Marrow via the Activation of the c-Jun N-Terminal Kinase Signaling Pathway. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.0708.v1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16483","DOI":"10.1074\/jbc.270.28.16483","article-title":"The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases *","volume":"270","author":"Karin","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rajabi, M., and Mousa, S.A. (2017). The Role of Angiogenesis in Cancer Treatment. Biomedicines, 5.","DOI":"10.3390\/biomedicines5020034"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhang, A.B., Mozaffari, K., Aguirre, B., Li, V., Kubba, R., Desai, N.C., Wei, D., Yang, I., and Wadehra, M. (2023). Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma. Cancers, 15.","DOI":"10.3390\/cancers15030830"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.humpath.2006.01.022","article-title":"c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer","volume":"37","author":"Vleugel","year":"2006","journal-title":"Hum. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/jnci\/djh148","article-title":"Angiogenesis and c-Jun","volume":"96","author":"Folkman","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-06-1863","article-title":"Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma","volume":"67","author":"Podar","year":"2007","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/emboj\/16.7.1695","article-title":"Induction of apoptosis by the transcription factor c-Jun","volume":"16","author":"Bakiri","year":"1997","journal-title":"Embo J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1078-0432.CCR-06-2216","article-title":"Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH2-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1\/2 Pathway","volume":"13","author":"Mhaidat","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1476-5381.2010.00746.x","article-title":"Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells","volume":"160","author":"Shieh","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.21873\/anticanres.16903","article-title":"Naringenin Induces Cellular Apoptosis in Melanoma Cells via Intracellular ROS Generation","volume":"44","author":"Fernando","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2014.10.043","article-title":"CD133(+) melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: Significance for melanoma treatment","volume":"357","author":"Sheehan","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/ds.DS-D-23-00208","article-title":"Hellebrigenin induces apoptosis by triggering cellular inhibitor of apoptosis 1 and Jun N-terminal kinase pathway in melanoma cells","volume":"42","author":"Shieu","year":"2024","journal-title":"Dermatol. Sin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2007.10.005","article-title":"Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species\/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells","volume":"259","author":"Wang","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1007\/s11033-014-3310-7","article-title":"Immune-related chemotactic factors were found in acute coronary syndromes by bioinformatics","volume":"41","author":"Zhang","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/fon-2016-0526","article-title":"Entinostat: A promising treatment option for patients with advanced breast cancer","volume":"13","author":"Connolly","year":"2017","journal-title":"Future Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13073-018-0597-3","article-title":"Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer","volume":"10","author":"Tanioka","year":"2018","journal-title":"Genome Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e124985","DOI":"10.1172\/jci.insight.124985","article-title":"JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer","volume":"6","author":"Ruiz","year":"2021","journal-title":"JCI Insight"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-024-02022-x","article-title":"JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression","volume":"23","author":"Redmer","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-Year Survival Rates for Treatment-Naive Patients with Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Dobosz, P., St\u0119pie\u0144, M., Golke, A., and Dzieci\u0105tkowski, T. (2022). Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052847"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Atsaves, V., Leventaki, V., Rassidakis, G.Z., and Claret, F.X. (2019). AP-1 Transcription Factors as Regulators of Immune Responses in Cancer. Cancers, 11.","DOI":"10.3390\/cancers11071037"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: A transcription factor comes of age","volume":"10","author":"Rao","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1820604116","article-title":"Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor","volume":"116","author":"Mognol","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-5793(03)00326-0","article-title":"NF-\u03baB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells","volume":"541","author":"Kim","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e20182009","DOI":"10.1084\/jem.20182009","article-title":"AP-1 activity induced by co-stimulation is required for chromatin opening during T cell activation","volume":"217","author":"Yukawa","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41590-020-0733-2","article-title":"Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1038\/ncomms3830","article-title":"A genome-wide regulatory network identifies key transcription factors for memory CD8\u207a T-cell development","volume":"4","author":"Hu","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1038\/s41467-022-30861-z","article-title":"Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells","volume":"13","author":"Mizukoshi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Hussein, M.S., Li, Q., Mao, R., Peng, Y., and He, Y. (2023). TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1114770"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2217\/imt-2022-0171","article-title":"Coexpression of C-Jun in Multiple-Chain DAP-CAR-engineered T-Cells for Solid Tumor Therapy","volume":"14","author":"Xu","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: Preclinical characterization and phase I trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/s41418-021-00765-4","article-title":"The AP-1 transcription factors c-Jun and JunB are essential for CD8\u03b1 conventional dendritic cell identity","volume":"28","author":"Novoszel","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"E9271","DOI":"10.1073\/pnas.1703921114","article-title":"Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner","volume":"114","author":"Mgrditchian","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13046-022-02559-z","article-title":"The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun","volume":"41","author":"Yu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_106","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1038\/s41467-018-07735-4","article-title":"JunB regulates homeostasis and suppressive functions of effector regulatory T cells","volume":"9","author":"Koizumi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","article-title":"JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ma, X.-M., Luo, Y.-F., Zeng, F.-F., Su, C., Liu, X., Li, X.-P., and Lu, J. (2022). TGF-\u03b21-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun\/STT3A Pathway in Nasopharyngeal Carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.815437"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"10348","DOI":"10.18632\/aging.205932","article-title":"Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing","volume":"16","author":"Wang","year":"2024","journal-title":"Aging"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/555\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:26:29Z","timestamp":1759919189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26020555"],"URL":"https:\/\/doi.org\/10.3390\/ijms26020555","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}